Protean BioDiagnostics, Inc. Partners with Qualisure Diagnostics, Inc.
Orlando, Florida – September 6, 2022
Protean BioDiagnostics enhances thyroid cancer care for patients with the addition of a new leading test to its Protean MAPS™ diagnostic menu.
Protean BioDiagnostics and Qualisure Diagnostics Inc. announced today that both companies have entered into a strategic partnership to launch a novel diagnostic test for thyroid cancer. Thyroid GuidePx® is the first genomic classifier for papillary thyroid cancer, designed to assist clinicians treating thyroid cancer in making treatment decisions. The test identifies patients with a very low risk of recurrence after surgery, and more accurately determines those at risk of cancer recurrence. Thyroid GuidePx® significantly outperforms the current standard of care which stratifies patient risk based on clinical and pathological factors. Thyroid GuidePx® testing will be performed by Orlando based Protean BioDiagnostics.
The agreement brings these partners together to lead the mission to personalize cancer care. Protean BioDiagnostics is an innovative precision medicine laboratory, and developer of the unique Protean MAPS™ System (Molecular Analysis Profiling System), a complete end-to-end diagnostic system designed to efficiently support treatment planning for cancer patients and oncologists. Qualisure Diagnostics Inc. is a company based in Calgary, Alberta, Canada that develops diagnostic tests for the purpose of personalizing cancer care.
Dr. Anthony Magliocco, CEO of Protean BioDiagnostics shared the following statement on the partnership;
“We are excited to partner with Qualisure Diagnostics to expand our mission to help patients with thyroid cancer obtain access to the diagnostic services they need to better guide their treatment choices. This is a historic day for Protean BioDiagnostics as we continue to expand access for cancer patients to revolutionary diagnostic services and transformative technologies like Thyroid GuidePx®.”
Patients and clinicians of Protean BioDiagnostics, Inc. will now be able to benefit from knowing that there is greater accuracy in identifying risk of recurrence of thyroid cancer after surgery.
Dr. Oliver Bathe, CEO of Qualisure Diagnostics, Inc. said,
“We believe that this test, and others that we have in development, will make Precision Oncology the standard of care for cancer patients in the very near future.”
For further information, please contact:
Anthony Magliocco MD
CEO & President of Protean BioDiagnostics
Email: info@proteanbiodx.com
Phone: 1 (813) 817 2042
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.